Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, gives us an update on the exciting PROMISE study, which performs a simple blood screening procedure on those at high-risk of developing myeloma, including African Americans and those with a family history of the disease. This would enable the early detection and treatment of MGUS and/or smoldering myeloma, with the aim of preventing disease progression. With the study well underway, she covers what has been found so far and how the results may effect practice. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.